7. Development of gene panel related to targeted treatment in Vietnamese lung cancer patients
Main Article Content
Abstract
Despite advancements in treatment, lung cancer continues to be a major contributor to global mortality. Tailoring treatment to individual patients using their sequencing data has shown to enhance symptom management and increase survival rates. Creating a gene panel, which is a compilation of crucial genes for diagnosis and treatment, is now a vital step in improving the efficacy of personalized lung cancer treatment. This study examines the COSMIC and CIVIC databases for gene mutations associated with lung cancer globally, and analyze the sequencing result of select patients at the Lung Hospital Center. Genetic mutations linked to targeted therapy were found in 43% of younger patients and 62% of older patients. Among the younger patients, the identified genetic mutations primarily involved driver genes, with EGFR at 28.6% and ALK at 14%. In contrast, older patients exhibited additional alterations such as KRAS at 24% and PIK3CA at 4%.
Article Details
Keywords
Bảng gen, Giải trình tự thế hệ mới, Ung thư phổi
References
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-249. doi:10.3322/caac.21660.
3. Halliday PR, Blakely CM, Bivona TG. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Curr Oncol Rep. 2019; 21(3): 21. doi:10.1007/s11912-019-0770-x.
4. Singh SS, Dahal A, Shrestha L, Jois SD. Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. Curr Med Chem. 2020; 27(32): 5274-5316. doi:10.2174/0929867326666190222183219.
5. Hasan GM, Hassan MdI, Sohal SS, Shamsi A, Alam M. Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma. ACS Omega. 2023; 8(30): 26685-26698. doi:10.1021/acsomega.3c02424.
6. Tsaousis GN, Papadopoulou E, Apessos A, et al. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations. BMC Cancer. 2019; 19(1): 535. doi:10.1186/s12885-019-5756-4.
7. Yatabe Y, Sunami K, Goto K, et al. Multiplex gene-panel testing for lung cancer patients. Pathol Int. 2020; 70(12): 921-931. doi:10.1111/pin.13023.
8. Murakami S, Yokose T, Shinada K, et al. Comparison of next - generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations. Thorac Cancer. 2022; 13(22): 3217-3224. doi:10.1111/1759-7714.14685.
9. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet Lond Engl. 2017; 389(10066): 299-311. doi:10.1016/S0140-6736(16)30958-8.
10. Stergiakouli E, Martin J, Hamshere ML, et al. Association between polygenic risk scores for attention-deficit hyperactivity disorder and educational and cognitive outcomes in the general population. Int J Epidemiol. 2017; 46(2): 421-428. doi:10.1093/ije/dyw216.
11. Pan X, Lv T, Zhang F, Fan H, Liu H, Song Y. Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2018; 20(9): 1168-1174. doi:10.1007/s12094-018-1838-z.
12. Suidan AM, Roisman L, Belilovski Rozenblum A, et al. Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival. J Glob Oncol. 2019; 5: 1-8. doi:10.1200/JGO.18.00216.